ALVENEX 20CPR 450MG

ALVENEX 450 MG

active ingredients

One tablet contains: active ingredient : diosmina 450 mg A bag contains: active ingredient : diosmin 450 mg For excipients, see 6.1

Excellent

ALVENEX 450 mg tablets Polyethyleneglycol 4000, Magnesium stearate (E572), Talco, Silice colloidal anidra. ALVENEX 450 mg oral suspension powder Fruit, Polyethyleneglycol 4000, Corn starch, Magnesium stearate (E572), Sweet Orange Essence.

Therapeutic indications

Symptoms attributable to venous failure; states of capillary fragility.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients. Pregnancy and nursing.

Population

A tablet or the contents of a bag ALVENEX twice a day, at regular intervals, except for different prescription. Methods of administration Tables: swallow the tablet with the help of a small amount of water. Oral Suspension Powder: disperse, by means of agitation, the content of a bag in little water (about half glass).

Conservation

No special precaution for conservation.

Warnings

There are no special precautions for the use of ALVENEX. For ALVENEX 450 mg powder for oral suspension: patients suffering from rare hereditary problems of fructose intolerance, should not take this medicine. Keep out of reach and sight of children.

Interactions

Particular interactions have not yet been detected. No interaction studies have been carried out.

Effects

Rarely use of ALVENEX at recommended doses in therapy gives rise to side effects. In any case, rare cases of gastralgia, nausea, diarrhea and dizziness are reported, always of a mild entity and such as not requiring the interruption of treatment.

Classification for Systems and Organs	Town	Not common	Rare	Very rare	Not Note (non-estimable frequency from available data)
Diseases of the nervous system			Vertigo, Cefalea, Malessere
Gastrointestinal diseases	Diarrhea, Dispepsia, Nausea, Vomito	Elite			Abdominal pain
Pathology of skin and subcutaneous tissue			Rash, Prurito, Orticaria		Edema to the face, to the lips, to the eyelids, Edema di Quincke
Emolinfopoietic system pathologies					Trombocytopenia

Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

No overdose cases have been reported.

The safety of the drug in pregnancy has not been determined; therefore it is appropriate not to administer the medicinal product during pregnancy.

Source: Farmadati